

רופא/ה, רוקח/ת נכבד/ה,

ברצוננו להודיעך על עדכון בעלון לרופא של **ZINFORO** :
זינפור

הודעה זו מפרטת את המידע הנוגע להרחבת ההתוויה לטיפול ביילדים מגיל לידה ועד גיל חודשיים (שינויים מסומנים בקו תחתון בגוף ההודעה), למידע מלא יש לעיין בעלון המאושר.

המרכיב הפעיל:

CEFTAROLINE FOSAMIL 600 mg

Indicated for:

Zinforo is indicated in ~~adults and children from age of 2 months~~ for the treatment of the following infections in neonates, infants, children, adolescents and adults :

- *Complicated skin and soft tissue infections (cSSTI)*
- *Community-acquired pneumonia (CAP)*

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

להלן העדכונים העיקריים בעלון לרופא:

4.2 Posology and method of administration

Posology

The recommended durations of treatment are 5-14 days for cSSTI and 5-7 days for CAP.

...

Table 2 Dosage in paediatric patients with normal renal function, creatinine clearance (CrCL) > 50 mL/min*

Indications	Age group	Posology (mg/infusion)	Infusion time (minutes)/Frequency
Complicated skin and soft tissue infections (cSSTI)	Adolescents aged from 12 to < 18 years with bodyweight ≥ 33 kg	600 mg	60/every 12 hours
	Adolescents aged from 12 years to < 18 years bodyweight < 33 kg and children ≥ 2 years to < 12 years	12 mg/kg to a maximum of 400 mg	60/every 8 hours
Community-acquired pneumonia (CAP)	Infants ≥ 2 months to < 2 years	8 mg/kg	60/every 8 hours
	<u>Neonates from birth to < 2 months^{a, b}</u>	<u>6 mg/kg</u>	<u>60/every 8 hours</u>

* Calculated using the Schwartz formula (in mL/min/1.73 m²) for paediatric patients.

^a Neonatal recommendations are based on pharmacokinetic and pharmacodynamic analyses only. See sections 4.4 and 5.1.

^b Based on preterm neonates at least 34 weeks gestational age and 12 days postnatal age

...

Special populations

...

Dose recommendations for **neonates (at least 34 weeks gestational age and 12 days postnatal age), infants, children and adolescents** are based on pharmacokinetic (PK) modelling.

There is insufficient information to recommend dosage adjustments in adolescents aged from 12 to < 18 years with bodyweight < 33 kg and in children aged from 2 to 12 years with End-stage renal disease (ESRD).

There is insufficient information to recommend dosage adjustments in paediatric patients ~~children aged from 2 months to~~ < 2 years with moderate or severe renal impairment or ESRD

4.4 Special warnings and precautions for use

...

The recommended dosage of Zinforo shown in Table 2 for paediatric patients < 2 months of age are based on pharmacokinetic-pharmacodynamic modelling and simulation.

4.8 Undesirable effects

...

Paediatric population

...

In addition, the safety assessment in neonates is based on the safety data from 2 trials in which 34 patients (age range from birth to less than 60 days) received Zinforo; 23 of these patients received only a single dose of Zinforo. Overall, the adverse events reported in these studies were consistent with the known safety profile for Zinforo.

...

5.2 Pharmacokinetic properties

...

Paediatric population

Dose adjustments are required for neonates, infants, children aged from 2 months to < 12 years and for adolescents aged 12 to < 18 years with bodyweight < 33 kg (see section 4.2). ~~The safety and efficacy of Zinforo in children aged birth to < 2 months have not been established.~~


...

כמו כן, בוצעו שינויים נוספים הכוללים תוספת מידע, השמטת מידע ועדכוני נוסח שאינם מהווים החמרה. העלונים המעודכנים זמינים באתר משרד הבריאות.

<https://www.gov.il/he/service/israeli-drug-index>

לחילופין, לקבלת עלון מלא מודפס ניתן לפנות לחברת פיזור PFE פרמצבטיקה ישראל בע"מ, שנקר 9, ת.ד. 12133 הרצליה פיתוח, 46725.

בברכה,
עידית שלם אבידר
רוקחת ממונה

DocuSigned by:

737B811FFB204E6...